TM4SF19 is a prognostic marker associated with immune invasion of bladder urothelial carcinoma
Research Square
2024
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Background Bladder Urothelial Carcinoma (BLCA) is a common urological cancer with significant morbidity and mortality. Thus, there is a need to discover novel biodiagnostic, therapeutic, and prognostic markers. The four-transmembrane L6 superfamily, which includes TM4SF19, has been implicated in cancer progression, but TM4SF19's role in BLCA remains unexplored. Method TM4SF19 expression was analyzed using data from TCGA databases. The cancer-promoting mechanism of TM4SF19 in BLCA was investigated by differential expression analysis, pathway enrichment analysis, immune infiltration analysis, and correlation analysis. The prognostic analysis of TM4SF19 in the TCGA-BLCA database was carried out to study its prognostic value. The mRNA expression of TM4SF19 was verified in bladder cancer cell lines and 30 peripheral blood samples of BLCA patients. The diagnostic value of TM4SF19 in the blood of BLCA patients was verified by receiver operating characteristic curve (ROC) analysis. Results TM4SF19 was found to be significantly overexpressed in BLCA cell lines, tumor tissue, and peripheral blood samples. ROC analysis indicated that TM4SF19 has diagnostic potential for BLCA patients. TM4SF19 expression was associated with immune cell infiltration, suggesting its impact on the tumor microenvironment. High TM4SF19 expression correlated with poor clinicopathological features and significantly reduced overall survival. Conclusion The upregulation of TM4SF19 has been observed to be correlated with the advancement of the disease and unfavorable prognosis. TM4SF19 is promised as a biomarker for the diagnosis and prognosis of BLCA patients, especially in peripheral blood testing.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know